Dr. Brad Bundy joined the BYU faculty in 2009 after completing his Ph.D. and M.S. degrees at Stanford University and B.S. at BYU (Summa Cum Laude) all in Chemical Engineering. He is the recipient of the NSF CAREER Award and DARPA Young Faculty Award.
His current research is focused in cell-free synthetic biology with six specific thrusts:
- Engineering On-Demand Distributed Production of Cancer Protein Theraputics at the Point of Care and at an affordable cost.
- Engineering Next-Generation Cancer Biotheraputics for improved pharmacokinetics (lower doses and less often with fewer side effects), stability, and efficacy.
- Streamlining and Lyophilizing Cell-free Synthetic Biology by developing more cost-effective and transferable techniques and technologies to make cell-free technology accessible to more scientists and researchers.
- Building Better Biocatalysts by developing technology for the rapid site-specific incorporation of unnatural amino acids into proteins for orientation-controlled covalent biocatalyst immobilization;
- Rewriting the Genetic Code by developing technology to directly control and manipulate the tRNA content.
- Vaccine Development by engineering and reengineering viruses and virus-like particles.